Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Journal: Nature medicine
Published: August 26, 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity.
Journal: The New England journal of medicine
Published: June 08, 2026
Correction: Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.
Journal: International journal of obesity (2005)
Published: May 29, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Journal: Nature medicine
Published: April 24, 2026
Interaction among GLP-1 signaling-related genetic variants suggests contribution to the control of appetitive traits among preadolescents.
Journal: Appetite
Published: February 20, 2026
International expert consensus on definitions and management of weight recurrence and suboptimal response after metabolic and bariatric surgery: a Delphi study.
Journal: Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
Published: December 18, 2025
The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy.
Journal: Obesity surgery
Published: October 04, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Journal: Diabetes, obesity & metabolism
Published: September 01, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: September 01, 2025
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Journal: Diabetes, obesity & metabolism
Published: August 08, 2025
Last Updated: 09/26/2026